Cases & Deals

Baxter International enters partnership with Brazilian company to expand access to recombinant FVIII hemophilia treatment

Clients Baxter International Inc.

Jones Day advised Baxter International Inc. as antitrust counsel in the negotiation of an exclusive 20-year partnership with Hemobrás (Empresa Brasileira de Hemoderivados e Biotechnologia) to provide hemophilia patients in Brazil greater access to recombinant factor VIII (rFVII) therapy for the treatment of hemophilia A.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.